Opioid-use Disorder
Conditions
Brief summary
The focus of this study is to examine the effectiveness of imFREE relative to mHealth ED in facilitating treatment retention and adherence and reducing opioid use among adults with OUD initiating BUP treatment. There are two specific aims: (1) to test the effectiveness of imFREE, delivered in conjunction with medical management with buprenorphine (imFREE + MM), relative to mHealth ED + MM, in facilitating buprenorphine treatment retention and adherence in a population of individuals with OUD initiating MM (N=200). (2) To evaluate the cost-effectiveness of imFREE.
Interventions
BEHAVIORALimFREE mCBT
The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
BEHAVIORALmHealth ED
The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
Sponsors
University of California, Los Angeles
University of California, San Diego
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 * DSM-5 diagnosis of OUD * no more than 2 weeks from the date of BUP induction * able to read and comprehend English at the 6th grade level (determined by REALM) * able to provide informed consent * presently owns a mobile phone that can send and receive text messages
Exclusion criteria
Participants must not have: 1. Life threatening or unstable medical illness requiring treatment or making participation difficult 2. Dependence on alcohol or other illicit substances for which medical detoxification is imminently needed 3. Presence of acute psychiatric symptoms warranting intensive treatment or hospitalization (e.g., acute suicidality or mania).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Medication Adherence self-report form. Unannounced medication count by phone | Monthly from date of randomization, for up to 6 months, or until study completion, whichever comes first. | Self-report of Treatment adherence to buprenorphine collected in self-report forms. Unannounced medication count by phone. Research staff will call participants and ask them to count out the remaining buprenorphine films left in their prescription. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DSM-V Checklist | Baseline | Assessing the presence of opiate use disorder |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSuzette Glasner, PhD
University of California, Los Angeles
Outcome results
None listed